Sleeve Gastrectomy Clinical Trials

Clinical trials related to Sleeve Gastrectomy Procedure

Comparison of Two-Year Weight-Loss Effectiveness of GLP-1 Receptor Agonists and Laparoscopic Sleeve Gastrectomy in the Treatment of Obesity: An Ambispective Propensity Score-Matched Cohort Study

Status: Recruiting
Location: See location...
Intervention Type: Procedure, Drug
Study Type: Observational
SUMMARY

This observational study will compare weight loss over two years in adults receiving GLP-1 receptor agonist medications with weight loss in adults who previously underwent laparoscopic sleeve gastrectomy, an operation that reduces the size of the stomach. Adults starting GLP-1 medications as part of their usual care will be followed for 24 months. Their results will be compared with existing medical records of adults who underwent sleeve gastrectomy at the same center. Treatment decisions will be made by patients and their treating clinicians as part of routine care, rather than assigned by the study. The main outcome is the percentage of starting body weight lost at 24 months. The study will also assess weight changes at earlier visits, medication side effects, treatment continuation and reasons for stopping treatment, and changes in weight-related health conditions. The groups will be matched using baseline characteristics to make the comparison more balanced.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

⁃ GLP-1 Receptor Agonist Cohort:

• Age 18 years or older at treatment initiation.

• Initiation of a GLP-1 receptor agonist for obesity or overweight as part of routine clinical care.

• Available baseline height and body weight measurements.

• Willingness to attend at least one follow-up assessment.

• Ability to comply with the center's standard follow-up program.

• Provision of written informed consent.

⁃ Laparoscopic Sleeve Gastrectomy Cohort:

• Age 18 years or older at surgery.

• Primary laparoscopic sleeve gastrectomy for obesity performed at the study center between January 1, 2020, and January 1, 2026.

• Available preoperative height, body weight, and body mass index measurements.

• Available demographic and baseline clinical data.

• At least one documented postoperative body weight measurement. Availability of a 24-month weight measurement is preferred for the primary comparison.

Locations
Other Locations
Turkey
Yüzüncü Yıl University
RECRUITING
Van
Contact Information
Primary
Sebahattin Çelik
s.celik@yyu.edu.tr
+90 505 705 79 57
Time Frame
Start Date: 2026-09-15
Estimated Completion Date: 2028-11-15
Participants
Target number of participants: 200
Treatments
GLP-1 Receptor Agonist Cohort
Adults aged 18 years or older starting a GLP-1 receptor agonist, such as liraglutide or semaglutide, for weight management as part of routine clinical care. Participants will be followed prospectively for 24 months, with assessments at baseline and months 1, 3, 6, 12, and 24. Weight changes, medication use, treatment adherence, adverse events, and treatment discontinuation will be recorded. Medication selection and dosing will be determined by the treating clinician independently of study participation.
Laparoscopic Sleeve Gastrectomy Cohort
Adults who underwent primary laparoscopic sleeve gastrectomy for obesity at the same center between January 1, 2020, and January 1, 2026, and were aged 18 years or older at surgery. Existing medical records will be reviewed retrospectively for baseline characteristics, postoperative weight measurements through 24 months, and surgical complications. This cohort will be matched with the GLP-1 receptor agonist cohort using propensity scores based on pretreatment characteristics. Surgery was performed as part of routine clinical care independently of this study.
Related Therapeutic Areas
Sponsors
Leads: Yuzuncu Yil University

This content was sourced from clinicaltrials.gov